Collaborative program with exclusive patent, know-how, process and technology license to make, have made, use, sell, offer, import and sublicense products based on certain compounds against specific targets, including Chk1 inhibitors having activity with a Ki, pKb or EC50 for enzymes and non-enzymatic receptor antagonists or agonists, including those candidate products that were refused or returned by the other party, and compounds that meet the activity threshold against biotherapeutic targets, for the fields of vascular biology-based disease, oncology and inflammatory disease, including inflammatory and malignant angiogenesis, ocular conditions, underlying malignant and pre-dysplastic, endometriosis, atherosclerosis, cardiac ischemia, congestive heart failure, renal disease, thrombosis, asthma, chronic obstructive pulmonary, pulmonary hypertension, and transplant rejection.

The text describes a collaborative licensing program that grants exclusive rights to manufacture and commercialize specific chemical compounds, such as Chk1 inhibitors, for treating various diseases. The agreement covers a broad range of therapeutic areas including oncology, vascular biology, and inflammatory conditions, with endometriosis explicitly listed among the target indications. This intellectual property arrangement is presented within the context of RoyaltyStat®, an online database used by professionals to analyze license agreements and royalty rates for transfer pricing and finance purposes. Relevance to endometriosis: listed as one indication for the licensed compounds, though the paper's main focus is on intellectual property valuation and database analytics rather than clinical research.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works